echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Urinary System > Dr. Xu Xianglai from Shanghai Zhongshan Hospital: Prostate stent has become a new choice for refractory urinary retention

    Dr. Xu Xianglai from Shanghai Zhongshan Hospital: Prostate stent has become a new choice for refractory urinary retention

    • Last Update: 2021-04-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Previously, in order to improve the professional skills of urology clinicians in my country and increase the opportunities for online communication, together with doctors to explore the focus of lower urinary tract symptoms (LUTS) related diseases and new ideas and new ideas for treatment, with the support of Pfizer , The "Medical Circle" media initiated the LUTS clinical research literature interpretation exchange project, soliciting clinical research interpretation and program design for the group of young doctors covered by the platform.

     After 3 months of fierce competition, a total of 3 young doctors came to the fore after being selected through the kick-off meeting, regional competitions, and finals.

    Here, the "medical community" specially invited one of the winners, Dr.
    Xu Xianglai, the attending physician of the Department of Urology, Zhongshan Hospital Affiliated to Fudan University, to review the content of his speech and give a brief introduction to his medical institution.

     Memokath prostate stent implantation to cope with repeated urinary retention An 86-year-old elderly male patient went to the hospital for more than a year due to repeated urinary retention.

    The patient had poor urination and a feeling of incomplete urination more than ten years ago.
    After taking finasteride and doxazosin, the symptoms improved.

    In the past year, her symptoms have significantly worsened and her urinary retention has been repeated.
    Currently, she has been indwelling catheterization for more than a month.

    The patient also suffered from hypertension for decades.
    Ten years ago, he had a coronary stent implanted for coronary artery stenosis.
    Five years ago, he received a stent graft for thoracic aortic dissection.
    Now he is treated with aspirinumab.

     Facing this patient with complicated cardiovascular disease and poor general condition, how to choose the most suitable treatment for the patient? After being admitted to the hospital, after careful clinical examination and evaluation, it was finally decided to implant a new spiral prostate stent for this patient.

    The patient returned to urinating spontaneously after the operation, and the residual urine was negative after three weeks, and the urine routine was normal.
    The patient is currently under long-term follow-up.

    Prostate stents originated from cardiovascular stents.
    The first prostate stent was used for urethral stricture caused by benign prostatic hyperplasia in 1980.

    In the 1990s, the mesh stent was introduced into China, but it was gradually eliminated due to poor long-term effects due to permanent implantation and inability to remove it.

    Later, the first generation of spiral stent appeared, which is easy to remove but easy to shift.
    The tightness of the spiral will also cause the prostatic apex epithelium to grow into the stent.

    At the beginning of this century, the second generation of spiral stent was improved after the first generation.
    The spiral is tighter, it is not easy to adhere to the mucosal epithelium, it is easier to remove and the incidence of displacement is low.

     Prostate stent application history At present, the Department of Urology, Zhongshan Hospital Affiliated to Fudan University has performed 29 cases of Memokath prostate stent implantation, and the operation time is 20-30 minutes.

    Diagram of Prostate Stent Implantation Department of Urology, Zhongshan Hospital Affiliated to Fudan University, Department of Urology, Zhongshan Hospital Affiliated to Fudan University, is a key discipline of the Ministry of Education, a key discipline for the third phase of the "211" and "985" projects, and a specialist in urology from the National Health Commission.
    Urology endoscopy diagnosis and treatment technology training base, one of the first batch of national doctoral degree awarding points.

    There are 102 ordinary beds open, and the annual operation volume is nearly 6000 cases, 90% of which are grade three and four (complex and difficult) operations and minimally invasive operations.

    The average hospital stay was only 6.
    14 days.

    The annual number of outpatient visits is more than 170,000, and the operation rate of inpatients is 96%.

     The Department of Urology, Zhongshan Hospital was founded in 1952 and is one of the earliest urology departments in China with independent wards.

    The founder is Professor Xiong Rucheng, a pioneer of Chinese urology.

    The Department of Urology, Zhongshan Hospital has a glorious history and has created many "firsts": the first domestic allogeneic kidney transplantation was successful and long-term survival; the first domestic extracorporeal shock wave lithotripsy was carried out and won the first prize of national scientific and technological progress; the earliest domestic Carry out laparoscopic urology operations, etc.

     In recent years, under the leadership of a new generation of academic leader and department director Professor Guo Jianming, the Department of Urology of Zhongshan Hospital has always maintained the domestic leading medical technology and scientific research level and in line with international standards with the concept of innovative development.

    Since Zhongshan Hospital launched the Da Vinci robot-assisted laparoscopic urological surgery earlier in China in 2009, it has completed nearly 700 robotic operations every year and has become the Da Vinci Robotic Chinese Urological Surgery Clinical Teaching Demonstration Center.

    Carry out zero ischemia laparoscopic partial nephrectomy, robot-assisted laparoscopic radical prostatectomy, total cystectomy, renal vein and vena cava thrombectomy and other difficult operations.

    Established a precise diagnosis and treatment system for kidney cancer, and won the second prize of Shanghai Science and Technology Progress Award.

    At present, it has subspecialty teams such as kidney tumor, prostate cancer, bladder cancer, urinary calculi, kidney transplantation, andrology, conducts MDT multidisciplinary collaboration, and undertakes a number of international multi-center clinical studies.

    Each year, he publishes more than 40 papers in well-known international and domestic journals.
    In the past three years, he has obtained 13 National Natural Science Funds, and his research fund has exceeded 10 million yuan.

     Inheriting tradition, developing advantages, strengthening characteristics, and establishing a leading domestic and internationally renowned urology center is the development goal of the Department of Urology of Zhongshan Hospital.

    Expert Profile Professor Guo Jianming, Chief Physician, Doctoral Supervisor, Director of Urology, Director of Urology, Zhongshan Hospital, Fudan University Introduction to the experts of the Standing Committee of the Reproductive Cancer Committee Zhu Yanjun, deputy chief physician of the Department of Urology, Zhongshan Hospital Affiliated to Fudan University, doctor of medicine, deputy director of the International Liaison and Cooperation Department, and director of international affairs.

    Member of the Committee of Experts of the Institute of Urology, Fudan University, Visiting scholar of the University of California, Davis, the Chinese edition of "BMJ Quality and Safety" Youth Editor, Shanghai May 4th Youth Medal Winner, has been engaged in urinary system tumors, stones and prostate diseases for a long time Diagnosis and treatment.

    Good at laparoscopic urological surgery, comprehensive treatment and full management of urinary tract tumors, early diagnosis of prostate cancer, and minimally invasive treatment of prostate hyperplasia.

    Ultrasound-guided transperineal prostate puncture was carried out earlier in China.

    New technologies such as diode dragon laser zero ischemia-preserving nephron surgery, prostate thermoforming stents, and prostate laser ablation have been carried out.

    He was awarded the National Second Prize of the First China Youth Urology Skills Competition, and was selected into the Rising Star China-Europe Outstanding Young Urology Exchange Program.
    He went to famous urology centers in France, Germany, Italy and the Czech Republic to exchange and study.

    Undertake the scientific research fund of Shanghai Science and Technology Commission and the young backbone scientific research fund of Fudan University.

    He has successively published more than 10 articles in domestic and foreign journals, among which 4 are included in SCI (the highest IF is 10.
    199 for a single article).

    Expert Profile Xu Xianglai, Attending Physician in Department of Urology, Zhongshan Hospital Affiliated to Fudan University, Zhejiang University, Ph.
    in Surgery, outstanding doctoral graduate, China Scholarship Council, the first author and first corresponding author of the joint Ph.
    Nearly 10 articles presided over the National Natural Science Youth Fund and the Zhongshan Youth Fund
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.